Showing results (411-420 of 428) with videos related to
Sort By:
Pageof 43
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.The Lancet. Oncology|March 10, 2023
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registryAlessio Cortellini, Josep Tabernero, Uma Mukherjee, et al.European Journal of Cancer (Oxford, England : 1990)|May 1, 2021
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European studyDavid J Pinato, Lorenza Scotti, Alessandra Gennari, et al.Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.International Journal of Cancer|July 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and DurvalumabMargherita Rimini, Angela Lamarca, Masafumi Ikeda, et al.Journal of the National Cancer Institute|April 13, 2022
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid RegistryAlessio Cortellini, Alessandra Gennari, Fanny Pommeret, et al.JAMA Oncology|November 24, 2021
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry, David J Pinato, Meera Patel, et al.Pageof 43